Hal Landy
Direttore Tecnico/Scientifico/R&S presso Valerion Therapeutics LLC
Posizioni attive di Hal Landy
Società | Posizione | Inizio | Fine |
---|---|---|---|
Valerion Therapeutics LLC
Valerion Therapeutics LLC Medical SpecialtiesHealth Technology Valerion Therapeutics LLC develops targeted therapies for orphan genetic diseases. The firm utilizes a proprietary antibody-mediated delivery platform to target therapies to specific tissues via a studied transport pathway. It therapies are based on an intracellular delivery technology platform that takes advantage of tissue targeting via an antibody and intracellular delivery dependent on membrane expression of a nucleoside transporter. The company was founded by Timothy S. Harris and Dustin D. Armstrong in 2007 and is headquartered in Concord, MA. | Direttore Tecnico/Scientifico/R&S | - | - |
Phoenicis Therapeutics, Inc.
Phoenicis Therapeutics, Inc. BiotechnologyHealth Technology Phoenicis Therapeutics, Inc. is a private company that is focused on developing therapies for rare dermatological disorders. The company is based in Hingham, MA. The company's goal is to improve the lives of those who suffer from these conditions. The CEO of the company is Deborah Ramsdell. | Direttore/Membro del Consiglio | - | - |
Storia della carriera di Hal Landy
Precedenti posizioni note di Hal Landy
Società | Posizione | Inizio | Fine |
---|---|---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Direttore Tecnico/Scientifico/R&S | 01/01/2007 | 01/01/2007 |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | Direttore Tecnico/Scientifico/R&S | 01/07/2009 | - |
EMD Serono, Inc.
EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA. | Direttore Tecnico/Scientifico/R&S | - | - |
REPLIGEN CORPORATION | Corporate Officer/Principal | - | - |
Formazione di Hal Landy
The Trustees of Columbia University in The City of New York | Doctorate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 7 |
Canada | 2 |
Posizioni
Chief Tech/Sci/R&D Officer | 4 |
Corporate Officer/Principal | 1 |
Doctorate Degree | 1 |
Settori
Health Technology | 7 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
REPLIGEN CORPORATION | Health Technology |
Aziende private | 5 |
---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
EMD Serono, Inc.
EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA. | Health Technology |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | Health Technology |
Valerion Therapeutics LLC
Valerion Therapeutics LLC Medical SpecialtiesHealth Technology Valerion Therapeutics LLC develops targeted therapies for orphan genetic diseases. The firm utilizes a proprietary antibody-mediated delivery platform to target therapies to specific tissues via a studied transport pathway. It therapies are based on an intracellular delivery technology platform that takes advantage of tissue targeting via an antibody and intracellular delivery dependent on membrane expression of a nucleoside transporter. The company was founded by Timothy S. Harris and Dustin D. Armstrong in 2007 and is headquartered in Concord, MA. | Health Technology |
Phoenicis Therapeutics, Inc.
Phoenicis Therapeutics, Inc. BiotechnologyHealth Technology Phoenicis Therapeutics, Inc. is a private company that is focused on developing therapies for rare dermatological disorders. The company is based in Hingham, MA. The company's goal is to improve the lives of those who suffer from these conditions. The CEO of the company is Deborah Ramsdell. | Health Technology |
- Borsa valori
- Insiders
- Hal Landy
- Esperienza